Publikationen 

Im Folgenden finden Sie ausgewählte Publikationen des KND.
 

Prof. Markus Otto

  1. Marques, T. M., Van Rumund, A., Oeckl, P., Kuiperij, H. B., Esselink, R. A. J., Bloem, B. R., … Verbeek, M. M. (2019). Serum NFL discriminates Parkinson disease from  atypical parkinsonisms. Neurology, 92(13), E1479–E1486. https://doi.org/10.1212/WNL.0000000000007179
  2. van der Ende, E. L., Meeter, L. H., Poos, J. M., Panman, J. L., Jiskoot, L. C., Dopper, E. G. P., … van Swieten, J. C. (2019). Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. The Lancet Neurology, 18(12), 1103–1111. https://doi.org/10.1016/S1474-4422(19)30354-0
  3. Oeckl, P., Halbgebauer, S., Anderl-Straub, S., Steinacker, P., Hussa, A. M., Neugebauer, H., … Otto, M. (2019). Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment. Journal of Alzheimer’s Disease, 67(2), 481–488. https://doi.org/10.3233/JAD-180325
  4. Sommerauer, M., Fedorova, T. D., Hansen, A. K., Knudsen, K., Otto, M., Jeppesen, J., … Borghammer, P. (2018). Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study. Brain : A Journal of Neurology, 141(2), 496–504. https://doi.org/10.1093/brain/awx348
  5. Steinacker, P., Anderl-Straub, S., Diehl-Schmid, J., Semler, E., Uttner, I., Von Arnim, C. A. F., … Otto, M. (2018). Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 91(15), E1390–E1401. https://doi.org/10.1212/WNL.0000000000006318

Prof. Dr. Christoph Laske

  1. Lee, S., Viqar, F., Zimmerman, M. E., Narkhede, A., Tosto, G., Benzinger, T. L. S., … Brickman, A. M. (2016). White matter hyperintensities are a core feature of Alzheimer’s disease: Evidence from the dominantly inherited Alzheimer network. Annals of Neurology, 79(6), 929–939. https://doi.org/10.1002/ana.24647
  2. Lim, Y. Y., Hassenstab, J., Cruchaga, C., Goate, A., Fagan, A. M., Benzinger, T. L. S., … Bateman, R. J. (2016). BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer’s disease. Brain, 139(10), 2766–2777. https://doi.org/10.1093/brain/aww200
  3. Franzmeier, N., Düzel, E., Jessen, F., Buerger, K., Levin, J., Duering, M., … Ewers, M. (2018). Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer’s disease. Brain : A Journal of Neurology, 141(4), 1186–1200. https://doi.org/10.1093/brain/awy008
  4. Chhatwal, J. P., Schultz, A. P., Johnson, K. A., Hedden, T., Jaimes, S., Benzinger, T. L. S., … Dominantly Inherited Alzheimer Network. (2018). Preferential degradation of cognitive networks differentiates Alzheimer’s disease from ageing. Brain : A Journal of Neurology, 141(5), 1486–1500. https://doi.org/10.1093/brain/awy053

Prof. Dr. Stefan Teipel

  1. Cavedo, E., Lista, S., Houot, M., Vergallo, A., Grothe, M. J., Teipel, S., … Hampel, H. (2020). Plasma tau correlates with basal forebrain atrophy rates in people at risk for alzheimer disease. Neurology, 94(1), e30–e41. https://doi.org/10.1212/WNL.0000000000008696
  2. Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., & Teipel, S. J. (2017). In vivo staging of regional amyloid deposition. Neurology, 89(20), 2031–2038. https://doi.org/10.1212/WNL.0000000000004643
  3. Thyrian, J. R., Hertel, J., Wucherer, D., Eichler, T., Michalowsky, B., Dreier-Wolfgramm, A., … Hoffmann, W. (2017). Effectiveness and safety of dementia care management in primary care: A randomized clinical trial. JAMA Psychiatry, 74(10), 996–1004. https://doi.org/10.1001/jamapsychiatry.2017.2124
  4. Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., … Winblad, B. (2017, August 1). Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. The Lancet Neurology, Vol. 16, pp. 661–676. https://doi.org/10.1016/S1474-4422(17)30159-X

Prof. Dr. Thomas Duning

  1. Johnen, A., Reul, S., Wiendl, H., Meuth, S. G., & Duning, T. (2018). Apraxia profiles—A single cognitive marker to discriminate all variants of frontotemporal lobar degeneration and Alzheimer’s disease. Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring, 10, 363–371. https://doi.org/10.1016/j.dadm.2018.04.002
  2. Pawlowski, M., Joksch, V., Wiendl, H., Meuth, S. G., Duning, T., & Johnen, A. (2018). Apraxia screening predicts Alzheimer pathology in frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 90(5), 562–569. https://doi.org/10.1136/jnnp-2018-318470
  3. Scheltens, P., Hallikainen, M., Grimmer, T., Duning, T., Gouw, A. A., Teunissen, C. E., … Prins, N. D. (2018). Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: Results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimer’s Research and Therapy, 10(1), 107. https://doi.org/10.1186/s13195-018-0431-6
  4. Reul, S., Lohmann, H., Wiendl, H., Duning, T., & Johnen, A. (2017). Can cognitive assessment really discriminate early stages of Alzheimer’s and behavioural variant frontotemporal dementia at initial clinical presentation? Alzheimer’s Research and Therapy, 9(1). https://doi.org/10.1186/s13195-017-0287-1

Prof. Dr. Janina Diehl-Schmid

  1. Oeckl, P., Halbgebauer, S., Anderl-Straub, S., Steinacker, P., Hussa, A. M., Neugebauer, H., … Otto, M. (2019). Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment. Journal of Alzheimer’s Disease, 67(2), 481–488. https://doi.org/10.3233/JAD-180325
  2. Bergeron, D., Gorno-Tempini, M. L., Rabinovici, G. D., Santos-Santos, M. A., Seeley, W., Miller, B. L., … Ossenkoppele, R. (2018). Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 84(5), 729–740. https://doi.org/10.1002/ana.25333
  3. Pottier, C., Zhou, X., Perkerson, R. B., Baker, M., Jenkins, G. D., Serie, D. J., … Rademakers, R. (2018). Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. The Lancet Neurology, 17(6), 548–558. https://doi.org/10.1016/S1474-4422(18)30126-1
  4. Steinacker, P., Anderl-Straub, S., Diehl-Schmid, J., Semler, E., Uttner, I., Von Arnim, C. A. F., … Otto, M. (2018). Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 91(15), E1390–E1401. https://doi.org/10.1212/WNL.0000000000006318
  5. Steinacker, P., Semler, E., Anderl-Straub, S., Diehl-Schmid, J., Schroeter, M. L., Uttner, I., … Otto, M. (2017). Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology, 88(10), 961–969. https://doi.org/10.1212/WNL.0000000000003688

Prof. Dr. Timo Grimmer

  1. Hartl, D., May, P., Gu, W., Mayhaus, M., Pichler, S., Spaniol, C., … Singleton, A. (2020). A rare loss-of-function variant of ADAM17 is associated with late-onset familial Alzheimer disease. Molecular Psychiatry, 25(3), 629–639. https://doi.org/10.1038/s41380-018-0091-8
  2. Alexopoulos, P., Thierjung, N., Economou, P., Werle, L., Buhl, F., Kagerbauer, S., … Perneczky, R. (2019). Plasma levels of soluble AβPPβ as a biomarker for Alzheimer’s disease with dementia. Journal of Alzheimer’s Disease, 69(1), 83–90. https://doi.org/10.3233/JAD-181088
  3. Scherr, M., Utz, L., Tahmasian, M., Pasquini, L., Grothe, M. J., Rauschecker, J. P., … Riedl, V. (2019). Effective connectivity in the default mode network is distinctively disrupted in Alzheimer’s disease—A simultaneous resting-state FDG-PET/fMRI study. Human Brain Mapping. https://doi.org/10.1002/hbm.24517
  4. Jansen, W. J., Ossenkoppele, R., Tijms, B. M., Fagan, A. M., Hansson, O., Klunk, W. E., … Zetterberg, H. (2018). Association of cerebral amyloid-β Aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry, 75(1), 84–95. https://doi.org/10.1001/jamapsychiatry.2017.3391
  5. Franzmeier, N., Göttler, J., Grimmer, T., Drzezga, A., Áraque-Caballero, M. A., Simon-Vermot, L., … Ewers, M. (2017). Resting-state connectivity of the left frontal cortex to the default mode and dorsal attention network supports reserve in mild cognitive impairment. Frontiers in Aging Neuroscience, 9(AUG), 264. https://doi.org/10.3389/fnagi.2017.00264

Prof. Dr. Robert Perneczky

  1. Schöberl, F., Pradhan, C., Irving, S., Buerger, K., Xiong, G., Kugler, G., … Zwergal, A. (2020). Real-space navigation testing differentiates between amyloid-positive and -negative aMCI. Neurology, 94(8), e861–e873. https://doi.org/10.1212/WNL.0000000000008758
  2. Rauchmann, B. S., Sadlon, A., & Perneczky, R. (2020). Soluble TREM2 and Inflammatory Proteins in Alzheimer’s Disease Cerebrospinal Fluid. Journal of Alzheimer’s Disease, 73(4), 1615–1626. https://doi.org/10.3233/JAD-191120
  3. Sadlon, A., Takousis, P., Alexopoulos, P., Evangelou, E., Prokopenko, I., & Perneczky, R. (2019, August 1). miRNAs Identify Shared Pathways in Alzheimer’s and Parkinson’s Diseases. Trends in Molecular Medicine, Vol. 25, pp. 662–672. https://doi.org/10.1016/j.molmed.2019.05.006
  4. Franzmeier, N., Ren, J., Damm, A., Monté-Rubio, G., Boada, M., Ruiz, A., … Ewers, M. (2019). The BDNF Val66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer’s disease. Molecular Psychiatry. https://doi.org/10.1038/s41380-019-0404-6
  5. Franzmeier, N., Göttler, J., Grimmer, T., Drzezga, A., Áraque-Caballero, M. A., Simon-Vermot, L., … Ewers, M. (2017). Resting-state connectivity of the left frontal cortex to the default mode and dorsal attention network supports reserve in mild cognitive impairment. Frontiers in Aging Neuroscience, 9(AUG), 264. https://doi.org/10.3389/fnagi.2017.00264

Prof. Dr. Lutz Frölich 

  1. Kunkle, B. W., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., … Pericak-Vance, M. A. (2019). Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 51(3), 414–430. https://doi.org/10.1038/s41588-019-0358-2
  2. van Maurik, I. S., Vos, S. J., Bos, I., Bouwman, F. H., Teunissen, C. E., Scheltens, P., … van der Flier, W. M. (2019). Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. The Lancet Neurology, 18(11), 1034–1044. https://doi.org/10.1016/S1474-4422(19)30283-2
  3. Atri, A., Frölich, L., Ballard, C., Tariot, P. N., Molinuevo, J. L., Boneva, N., … Cummings, J. L. (2018). Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease three randomized clinical trials. JAMA - Journal of the American Medical Association, 319(2), 130–142. https://doi.org/10.1001/jama.2017.20373
  4. Bos, I., Vos, S. J., Frölich, L., Kornhuber, J., Wiltfang, J., Maier, W., … Visser, P. J. (2017). The frequency and influence of dementia risk factors in prodromal Alzheimer’s disease. Neurobiology of Aging, 56, 33–40. https://doi.org/10.1016/j.neurobiolaging.2017.03.034
  5. Frölich, L., Peters, O., Lewczuk, P., Gruber, O., Teipel, S. J., Gertz, H. J., … Kornhuber, J. (2017). Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia. Alzheimer’s Research and Therapy, 9(1), 84. https://doi.org/10.1186/s13195-017-0301-7

Prof. Dr. Emrah Düzel

  1. Bainbridge, W. A., Berron, D., Schütze, H., Cardenas-Blanco, A., Metzger, C., Dobisch, L., … Düzel, E. (2019). Memorability of photographs in subjective cognitive decline and mild cognitive impairment: Implications for cognitive assessment. Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring, 11, 610–618. https://doi.org/10.1016/j.dadm.2019.07.005
  2. Betts, M. J., Kirilina, E., Otaduy, M. C. G., Ivanov, D., Acosta-Cabronero, J., Callaghan, M. F., … Hämmerer, D. (2019). Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain : A Journal of Neurology, 142(9), 2558–2571. https://doi.org/10.1093/brain/awz193
  3. Franzmeier, N., Ren, J., Damm, A., Monté-Rubio, G., Boada, M., Ruiz, A., … Ewers, M. (2019). The BDNF Val66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer’s disease. Molecular Psychiatry. https://doi.org/10.1038/s41380-019-0404-6
  4. Düzel, E., Berron, D., Schütze, H., Cardenas-Blanco, A., Metzger, C., Betts, M., … Jessen, F. (2018). CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring, 10, 782–790. https://doi.org/10.1016/j.dadm.2018.10.003
  5. Franzmeier, N., Düzel, E., Jessen, F., Buerger, K., Levin, J., Duering, M., … Ewers, M. (2018). Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer’s disease. Brain : A Journal of Neurology, 141(4), 1186–1200. https://doi.org/10.1093/brain/awy008

Priv.-Doz. Dr. Özgür Onur

  1. Hoenig, M. C., Bischof, G. N., Onur, Ö. A., Kukolja, J., Jessen, F., Fliessbach, K., … Alzheimer’s Disease Neuroimaging Initiative. (2019). Level of education mitigates the impact of tau pathology on neuronal function. European Journal of Nuclear Medicine and Molecular Imaging, 46(9), 1787–1795. https://doi.org/10.1007/s00259-019-04342-3
  2. Hoenig, M. C., Bischof, G. N., Seemiller, J., Hammes, J., Kukolja, J., Onur, Ö. A., … Drzezga, A. (2018). Networks of tau distribution in Alzheimer’s disease. Brain : A Journal of Neurology, 141(2), 568–581. https://doi.org/10.1093/brain/awx353
  3. Richter, N., Beckers, N., Onur, O. A., Dietlein, M., Tittgemeyer, M., Kracht, L., … Kukolja, J. (2018). Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease. Brain : A Journal of Neurology, 141(3), 903–915. https://doi.org/10.1093/brain/awx356
  4. Dronse, J., Fliessbach, K., Bischof, G. N., Von Reutern, B., Faber, J., Hammes, J., … Drzezga, A. (2017). In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer’s Disease. Journal of Alzheimer’s Disease, 55(2), 465–471. https://doi.org/10.3233/JAD-160316

Prof. Dr. Frank Jessen

  1. Kunkle, B. W., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., … Pericak-Vance, M. A. (2019). Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 51(3), 414–430. https://doi.org/10.1038/s41588-019-0358-2
  2. Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., … Silverberg, N. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018
  3. Jessen, F., Spottke, A., Boecker, H., Brosseron, F., Buerger, K., Catak, C., … Düzel, E. (2018). Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE). Alzheimer’s Research and Therapy, 10(1), 15. https://doi.org/10.1186/s13195-017-0314-2
  4. Dronse, J., Fliessbach, K., Bischof, G. N., Von Reutern, B., Faber, J., Hammes, J., … Drzezga, A. (2017). In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer’s Disease. Journal of Alzheimer’s Disease, 55(2), 465–471. https://doi.org/10.3233/JAD-160316
  5. Molinuevo, J. L., Rabin, L. A., Amariglio, R., Buckley, R., Dubois, B., Ellis, K. A., … Jessen, F. (2017). Implementation of subjective cognitive decline criteria in research studies. Alzheimer’s and Dementia, Vol. 13, pp. 296–311. https://doi.org/10.1016/j.jalz.2016.09.012

Prof. Dr. Agnes Flöel

  1. Gerischer, L. M., Fehlner, A., Köbe, T., Prehn, K., Antonenko, D., Grittner, U., … Flöel, A. (2018). Combining viscoelasticity, diffusivity and volume of the hippocampus for the diagnosis of Alzheimer’s disease based on magnetic resonance imaging. NeuroImage: Clinical, 18, 485–493. https://doi.org/10.1016/j.nicl.2017.12.023
  2. Schwarz, C., Stekovic, S., Wirth, M., Benson, G., Royer, P., Sigrist, S. J., … Flöel, A. (2018). Safety and tolerability of spermidine supplementation in mice and older adults with subjective cognitive decline. Aging, 10(1), 19–33. https://doi.org/10.18632/aging.101354
  3. Wirth, M., Benson, G., Schwarz, C., Köbe, T., Grittner, U., Schmitz, D., … Flöel, A. (2018). The effect of spermidine on memory performance in older adults at risk for dementia: A randomized controlled trial. Cortex, 109, 181–188. https://doi.org/10.1016/j.cortex.2018.09.014
  4. Antonenko, D., Schubert, F., Bohm, F., Ittermann, B., Aydin, S., Hayek, D., … Flöel, A. (2017). tDCS-induced modulation of GABA levels and resting-state functional connectivity in older adults. Journal of Neuroscience, 37(15), 4065–4073. https://doi.org/10.1523/JNEUROSCI.0079-17.2017
  5. Ladenbauer, J., Ladenbauer, J., Külzowä, N., De Boor, R., Avramova, E., Grittner, U., & Flöel, A. (2017). Promoting sleep oscillations and their functional coupling by transcranial stimulation enhances memory consolidation in mild cognitive impairment. Journal of Neuroscience, 37(30), 7111–7124. https://doi.org/10.1523/JNEUROSCI.0260-17.2017

Prof. Dr. Jens Wiltfang

  1. Kleineidam, L., Chouraki, V., Próchnicki, T., van der Lee, S. J., Madrid-Márquez, L., Wagner-Thelen, H., … Ramirez, A. (2020). PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica, 1–20. https://doi.org/10.1007/s00401-020-02138-6
  2. Franzmeier, N., Ren, J., Damm, A., Monté-Rubio, G., Boada, M., Ruiz, A., … Ewers, M. (2019). The BDNF Val66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer’s disease. Molecular Psychiatry. https://doi.org/10.1038/s41380-019-0404-6
  3. Kunkle, B. W., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., … Pericak-Vance, M. A. (2019). Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 51(3), 414–430. https://doi.org/10.1038/s41588-019-0358-2
  4. van Maurik, I. S., Vos, S. J., Bos, I., Bouwman, F. H., Teunissen, C. E., Scheltens, P., … van der Flier, W. M. (2019). Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. The Lancet Neurology, 18(11), 1034–1044. https://doi.org/10.1016/S1474-4422(19)30283-2
  5. Jansen, W. J., Ossenkoppele, R., Tijms, B. M., Fagan, A. M., Hansson, O., Klunk, W. E., … Zetterberg, H. (2018). Association of cerebral amyloid-β Aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry, 75(1), 84–95. https://doi.org/10.1001/jamapsychiatry.2017.3391

Prof. Dr. Christine von Arnim

  1. Hooshmand, B., Refsum, H., Smith, A. D., Kalpouzos, G., Mangialasche, F., Von Arnim, C. A. F., … Fratiglioni, L. (2019). Association of Methionine to Homocysteine Status with Brain Magnetic Resonance Imaging Measures and Risk of Dementia. JAMA Psychiatry, 76(11), 1198–1205. https://doi.org/10.1001/jamapsychiatry.2019.1694
  2. Gomes, L. A., Hipp, S. A., Rijal Upadhaya, A., Balakrishnan, K., Ospitalieri, S., Koper, M. J., … Thal, D. R. (2019). Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein. Acta Neuropathologica, 138(6), 913–941. https://doi.org/10.1007/s00401-019-02053-5
  3. Hecht, M., Krämer, L. M., von Arnim, C. A. F., Otto, M., & Thal, D. R. (2018). Capillary cerebral amyloid angiopathy in Alzheimer’s disease: association with allocortical/hippocampal microinfarcts and cognitive decline. Acta Neuropathologica, 135(5), 681–694. https://doi.org/10.1007/s00401-018-1834-y
  4. Küster, O. C., Laptinskaya, D., Fissler, P., Schnack, C., Zügel, M., Nold, V., … Von Arnim, C. A. F. (2017). Novel Blood-Based Biomarkers of Cognition, Stress, and Physical or Cognitive Training in Older Adults at Risk of Dementia: Preliminary Evidence for a Role of BDNF, Irisin, and the Kynurenine Pathway. Journal of Alzheimer’s Disease, 59(3), 1097–1111. https://doi.org/10.3233/JAD-170447

Prof. Dr. Richard Dodel 

  1. Dodel, R. (2017, December 5). Comment: β-Amyloid pathology and Parkinson disease. Neurology, Vol. 89, p. 2339. https://doi.org/10.1212/WNL.0000000000004756
  2. Handels, R. L. H., Wimo, A., Dodel, R., Kramberger, M. G., Visser, P. J., Molinuevo, J. L., … Winblad, B. (2017). Cost-Utility of Using Alzheimer’s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. Journal of Alzheimer’s Disease, 60(4), 1477–1487. https://doi.org/10.3233/JAD-170324
  3. Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., … Bordelon, Y. (2017). Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 32(6), 853–864. https://doi.org/10.1002/mds.26987
  4. Respondek, G., Kurz, C., Arzberger, T., Compta, Y., Englund, E., Ferguson, L. W., … Höglinger, G. U. (2017). Which ante mortem clinical features predict progressive supranuclear palsy pathology? Movement Disorders, 32(7), 995–1005. https://doi.org/10.1002/mds.27034

Prof. Dr. Johannes Kornhuber

  1. Kunkle, B. W., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., … Pericak-Vance, M. A. (2019). Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 51(3), 414–430. https://doi.org/10.1038/s41588-019-0358-2
  2. Lewczuk, P., Ermann, N., Andreasson, U., Schultheis, C., Podhorna, J., Spitzer, P., … Zetterberg, H. (2018). Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimer’s Research and Therapy, 10(1), 1–10. https://doi.org/10.1186/s13195-018-0404-9
  3. Frölich, L., Peters, O., Lewczuk, P., Gruber, O., Teipel, S. J., Gertz, H. J., … Kornhuber, J. (2017). Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia. Alzheimer’s Research and Therapy, 9(1), 84. https://doi.org/10.1186/s13195-017-0301-7
  4. Lewczuk, P., Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. L., Eusebi, P., … Fagan, A. M. (2017). Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 55(2), 813–822. https://doi.org/10.3233/JAD-160722
  5. Sims, R., Van Der Lee, S. J., Naj, A. C., Bellenguez, C., Badarinarayan, N., Jakobsdottir, J., … Schellenberg, G. D. (2017). Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nature Genetics, 49(9), 1373–1384. https://doi.org/10.1038/ng.3916

Prof. Dr. Michael Heneka 

  1. Heneka, M. T., McManus, R. M., & Latz, E. (2018). Inflammasome signalling in brain function and neurodegenerative disease. Nature Reviews Neuroscience, Vol. 19, pp. 610–621. https://doi.org/10.1038/s41583-018-0055-7
  2. Labzin, L. I., Heneka, M. T., & Latz, E. (2018). Innate Immunity and Neurodegeneration. Annual Review of Medicine, 69(1), 437–449. https://doi.org/10.1146/annurev-med-050715-104343
  3. Netea, M. G., Balkwill, F., Chonchol, M., Cominelli, F., Donath, M. Y., Giamarellos-Bourboulis, E. J., … Dinarello, C. A. (2017, July 19). A guiding map for inflammation. Nature Immunology, Vol. 18, pp. 826–831. https://doi.org/10.1038/ni.3790
  4. Sarlus, H., & Heneka, M. T. (2017, September 1). Microglia in Alzheimer’s disease. Journal of Clinical Investigation, Vol. 127, pp. 3240–3249. https://doi.org/10.1172/JCI90606
  5. Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R., Tejera, D., … Heneka, M. T. (2017). Microglia-derived ASC specks crossseed amyloid-β in Alzheimer’s disease. Nature, 552(7685), 355–361. https://doi.org/10.1038/nature25158 

Prof. Dr. Anja Schneider

  1. Gong, J., Szego, É. M., Leonov, A., Benito, E., Becker, S., Fischer, A., … Schneider, A. (2019). Translocator protein ligand protects against neurodegeneration in the MPTP mouse model of parkinsonism. Journal of Neuroscience, 39(19), 3752–3769. https://doi.org/10.1523/JNEUROSCI.2070-18.2019
  2. Audano, M., Schneider, A., & Mitro, N. (2018). Mitochondria, lysosomes, and dysfunction: their meaning in neurodegeneration. Journal of Neurochemistry, 147(3), 291–309. https://doi.org/10.1111/jnc.14471
  3. Bartels, C., Wagner, M., Wolfsgruber, S., Ehrenreich, H., & Schneider, A. (2018). Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer’s dementia in individuals with previous depression. American Journal of Psychiatry, 175(3), 232–241. https://doi.org/10.1176/appi.ajp.2017.17040404
  4. Wang, Y., Balaji, V., Kaniyappan, S., Krüger, L., Irsen, S., Tepper, K., … Mandelkow, E. M. (2017). The release and trans-synaptic transmission of Tau via exosomes. Molecular Neurodegeneration, 12(1), 5. https://doi.org/10.1186/s13024-016-0143-y

Prof. Dr. Oliver Peters

  1. Kleineidam, L., Chouraki, V., Próchnicki, T., van der Lee, S. J., Madrid-Márquez, L., Wagner-Thelen, H., … Ramirez, A. (2020). PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica, 1–20. https://doi.org/10.1007/s00401-020-02138-6
  2. van Maurik, I. S., Vos, S. J., Bos, I., Bouwman, F. H., Teunissen, C. E., Scheltens, P., … van der Flier, W. M. (2019). Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. The Lancet Neurology, 18(11), 1034–1044. https://doi.org/10.1016/S1474-4422(19)30283-2
  3. Kunkle, B. W., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., … Pericak-Vance, M. A. (2019). Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 51(3), 414–430. https://doi.org/10.1038/s41588-019-0358-2
  4. Jansen, W. J., Ossenkoppele, R., Tijms, B. M., Fagan, A. M., Hansson, O., Klunk, W. E., … Zetterberg, H. (2018). Association of cerebral amyloid-β Aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry, 75(1), 84–95. https://doi.org/10.1001/jamapsychiatry.2017.3391
  5. Frölich, L., Peters, O., Lewczuk, P., Gruber, O., Teipel, S. J., Gertz, H. J., … Kornhuber, J. (2017). Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia. Alzheimer’s Research and Therapy, 9(1), 84. https://doi.org/10.1186/s13195-017-0301-7
  6. Sims, R., Van Der Lee, S. J., Naj, A. C., Bellenguez, C., Badarinarayan, N., Jakobsdottir, J., … Schellenberg, G. D. (2017). Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nature Genetics, 49(9), 1373–1384. https://doi.org/10.1038/ng.3916

Prof. Dr. Dr. Frank Schneider

  1. Ellendt, S., Voβ, B., Kohn, N., Wagels, L., Goerlich, K. S., Drexler, E., … Habel, U. (2016). Predicting Stability of Mild Cognitive Impairment (MCI): Findings of a Community Based Sample. Current Alzheimer Research, 14(6), 608–619. https://doi.org/10.2174/1567205014666161213120807

Prof. Dr. Jörg B. Schulz

  1. Wojtala, J., Heber, I. A., Neuser, P., Heller, J., Kalbe, E., Rehberg, S. P., … Reetz, K. (2019). Cognitive decline in Parkinson’s disease: The impact of the motor phenotype on cognition. Journal of Neurology, Neurosurgery and Psychiatry, 90(2), 171–179. https://doi.org/10.1136/jnnp-2018-319008
  2. Jacobi, H., du Montcel, S. T., Bauer, P., Giunti, P., Cook, A., Labrum, R., … Klockgether, T. (2018). Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias. Journal of Neurology, 265(9), 2040–2051. https://doi.org/10.1007/s00415-018-8954-0
  3. Heller, J., Brcina, N., Dogan, I., Holtbernd, F., Romanzetti, S., Schulz, J. B., … Reetz, K. (2017). Brain imaging findings in idiopathic REM sleep behavior disorder (RBD) – A systematic review on potential biomarkers for neurodegeneration. Sleep Medicine Reviews, Vol. 34, pp. 23–33. https://doi.org/10.1016/j.smrv.2016.06.006

Prof. Dr. Kathrin Reetz

  1. Teuber-Hanselmann, S., Rekowski, J., Vogelgsang, J., Von Arnim, C., Reetz, K., Stang, A., … Keyvani, K. (2020). CSF and blood kallikrein-8: A promising early biomarker for Alzheimer’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 91(1), 40–48. https://doi.org/10.1136/jnnp-2019-321073
  2. Wojtala, J., Heber, I. A., Neuser, P., Heller, J., Kalbe, E., Rehberg, S. P., … Reetz, K. (2019). Cognitive decline in Parkinson’s disease: The impact of the motor phenotype on cognition. Journal of Neurology, Neurosurgery and Psychiatry, 90(2), 171–179. https://doi.org/10.1136/jnnp-2018-319008
  3. Hohenfeld, C., Werner, C. J., & Reetz, K. (2018). Resting-state connectivity in neurodegenerative disorders: Is there potential for an imaging biomarker? NeuroImage: Clinical, Vol. 18, pp. 849–870. https://doi.org/10.1016/j.nicl.2018.03.013
  4. Reetz, K., Rodríguez-Labrada, R., Dogan, I., Mirzazade, S., Romanzetti, S., Schulz, J. B., … Velázquez-Pérez, L. (2018). Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2. Annals of Clinical and Translational Neurology, 5(2), 128–137. https://doi.org/10.1002/acn3.504
  5. Moss, D. J. H., Tabrizi, S. J., Mead, S., Lo, K., Pardiñas, A. F., Holmans, P., … Tan, L. (2017). Identification of genetic variants associated with Huntington’s disease progression: a genome-wide association study. The Lancet Neurology, 16(9), 701–711. https://doi.org/10.1016/S1474-4422(17)30161-8

Veranstaltungen und Termine

B.R.A.I.N. lectures

03.09.2020
Online Seminar Serie
mehr

30. Konferenz von Alzheimer Europe: "Dementia in a changing world"

20.10.2020 - 22.10.2020
Online Konferenz
mehr

14th World Congress on Controversies in Neurology (CONy)

29.10.2020 - 01.11.2020
Online Kongress
mehr

Aktuelle Informationen und Artikel

Alzheimer: Erinnerungen sind möglicherweise nur überlagert

07.08.2020 - Deutsches Ärzteblatt

Einen Mechanismus, der die gestörte Erinnerung bei einer Alzheimer-Erkrankung mitverursachen könnte, beschreiben Wissenschaftler um Martin Fuhrmann vom Deutschen Zentrum für Neurodegenerative Erkrankungen (DZNE; Studie veröffentlicht in Nature). Danach stören Nervenzellen im Gehirn, die für neue Erfahrungen zuständig sind, die Signale von Zellen, die Erinnerungen enthalten und legen eigene Signale darüber. 

auf Deutsches Ärzteblatt weiterlesen

Bluttest erkennt Morbus Alzheimer bis zu 20 Jahre vor ersten kognitiven Störungen

05.08.2020 - Deutsches Ärzteblatt

Ein neuer Bluttest, der Bruchstücke des für die Erkrankung typi­schen Tau-Proteins nachweist, hat in 2 Studien einen Morbus Alzheimer ebenso zuver­lässig erkannt wie die derzeitigen Standardtests, die aufgrund ihrer Invasivität oder Kosten nicht als Screeningtest infrage kommen

auf Deutsches Ärzteblatt weiterlesen

Neue Erkenntnisse über subjektiv empfundene Gedächtnisprobleme

16.07.2020 - Neurology
Ein Forschungsteam unter Federführung des Deutschen Zentrums für Neurodegenerative Erkrankungen (DZNE) kommt zu dem Schluss, dass die persönliche Wahrnehmung ein wichtiges Indiz sein kann, um eine Alzheimer-Erkrankung frühzeitig zu bemerken.
auf Neurology weiterlesen

Bundesregierung beschließt Nationale Demenzstrategie

01.07.2020 - Nationale Demenzstrategie

Das Bundeskabinett hat heute die Nationale Demenzstrategie verabschiedet. In einem breiten Bündnis macht sich die Bundesregierung damit auf den Weg, Deutschland demenzfreundlich zu gestalten. Zusammen mit den Partnern soll im September der Startschuss gegeben werden, dann beginnt die konkrete Umsetzung, 2026 wird Bilanz gezogen.

auf Nationale Demenzstrategie weiterlesen

Aktuelle Rekrutierung

Aktuell sucht die Eisai Studie Probanden.
 
Diese Studie untersucht die Wirksamkeit eines neuen Medikaments für Patient*innen im frühen Stadium der Alzheimer-Krankheit gegenüber einem Placebo und wird an mehreren Gedächtnisambulanzen in Deutschland durchgeführt.

Auschreibung Alzheimer-Promotionsstipendien 2021

Die Hans und Ilse Breuer-Stiftung hat die Ausschreibung der Promotionsstipendien 2021 gestartet. Gefördert werden Promotionsvorhaben, die an einem der zehn Standorte des Deutschen Zentrum für Neurodegenerative Erkrankungen (DZNE) durchgeführt werden und sich der Erforschung der Linderung und Heilung der Alzheimer-Krankheit oder ähnlicher Alterserkrankungen widmen.

Bewerbungen sind an das Kuratorium der Stiftung in englischer Sprache bis zum 30. September 2020 elektronisch unter info@breuerstiftung.de möglich. Weitere Informationen finden Sie auf der Webseite der Hans und Ilse Breuer-Stiftung (www.breuerstiftung.de).